Methods of treating tardive dyskinesia and other movement disorders using NMDA receptor antagonists

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 6057373
SERIAL NO

09224829

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention describes a novel treatment for movement disorders, including tardive dyskinesia and tardive dystonia, and focal dystonias not due to neuroleptics, including blepharospasm, Meige syndrome, and occupational dystonias. The treatment of the present invention utilizes agents that act as NMDA-type glutamate receptor antagonists The invention also involves the use of an ion channel blocking agent to augment the therapeutic action of the drug treatments described. A particularly preferred ion channel blocking agent is magnesium.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddressTotal Patents
SYNCHRONEURON INC.LEXINGTON, MA11

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Fogel, Barry S Waban, MA 25 311

Cited Art Landscape

Patent Info (Count) # Cites Year
 
Other [Check patent profile for assignment information] (1)
* 5604198 Method to enhance permeability of the blood/brain blood/nerve barriers to therapeutic agents 45 1994
 
MERZ + CO. GMBH & CO. (1)
* 5262162 Cerebral-activating extract 11 1991
 
RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC. (1)
* 5602150 Treatment of central nervous system disorders associated with psychotic behavior and dementia with a combination of neuroleptic drugs and taurine, or derivatives thereof, to prevent the development of tardive dyskinesia 14 1995
 
LIPHA SA (1)
* 4355043 Novel derivatives of 3-aminopropanesulfonic acid having a reinforced activity on membrane 24 1980
 
PODUSLO, JOSEPH F. (1)
* 5670477 Method to enhance permeability of the blood/brain blood/nerve bariers to therapeutic agents 57 1995
 
CHILDREN'S MEDICAL CENTER CORPORATION (3)
* 5455279 Regimen method of mediating neuronal damage using nitroglycerine 16 1993
* 5747545 Method of preventing NMDA receptor complex-mediated Neuronal damage 9 1995
* 5614560 Method of preventing NMDA receptor-mediated neuronal damage 43 1995
 
CENTER FOR NEUROLOGIC STUDY NOT-FOR-PROFIT RESEARCH FOUNDATION OF CALIFORNIA (1)
* 5206248 Method for reducing emotional lability 34 1992
 
MERZ PHARMA GMBH & CO. KGAA (2)
* 5061703 Adamantane derivatives in the prevention and treatment of cerebral ischemia 42 1990
* 5382601 Memantine-containing solid pharmaceutical dosage forms having an extended two-stage release profile and production thereof 39 1993
* Cited By Examiner

Patent Citation Ranking

Forward Cite Landscape

Patent Info (Count) # Cites Year
 
Other [Check patent profile for assignment information] (3)
* 2002/0165,246 Administration of sleep restorative agents 23 2002
* 2006/0251,717 Memantine Oral Dosage Forms 3 2006
* 2008/0089,859 ADMINISTRATION OF SLEEP RESTORATIVE AGENTS 6 2007
 
YALE UNIVERSITY (2)
8778979 Glutamate agents in the treatment of mental disorders 0 2006
* 2006/0270,647 Glutamate agents in the treatment of mental disorders 6 2006
 
Robert J. DeLorenzo (1)
* 2005/0153,930 Inhibition of a novel calcium injury current that forms in nuerons during injury prevents neuronal cell death 0 2004
 
KANGWON NATIONAL UNIVERSITY UNIVERSITY-INDUSTRY COOPERATION FOUNDATION (2)
7691874 Neuroprotective properties of dextrorotatory morphinans 0 2005
* 2005/0256,147 NEUROPROTECTIVE PROPERTIES OF DEXTROROTATORY MORPHINANS 5 2005
 
Nueronetics, Inc. (1)
7857746 System and method to reduce discomfort using nerve stimulation 5 2004
 
SYNCHRONEURON INC. (3)
9421178 Acamprosate formulations, methods of using the same, and combinations comprising the same 0 2013
9421179 Acamprosate formulations, methods of using the same, and combinations comprising the same 0 2013
9427420 Acamprosate formulations, methods of using the same, and combinations comprising the same 0 2014
 
WARNER-LAMBERT COMPANY LLC (1)
6942876 Analgesic compositions comprising anti-epileptic compounds and methods of using same 5 2002
 
MERZ PHARMA GMBH & CO. KGAA (1)
* 2008/0279,896 Treatment of movement disorders by a combined use of chemodenervating agent and automated movement therapy 10 2008
 
JUVENTUS BIOSCIENCE, LLC (1)
* 2004/0037,895 Methods of treating involuntary facial spasms and facial wrinkles 1 2003
 
FOREST LABORATORIES, INC. (1)
* 2010/0028,427 IMMEDIATE RELEASE FORMULATIONS OF 1-AMINOCYCLOHEXANE COMPOUNDS, MEMANTINE AND NERAMEXANE 0 2009
 
FOREST LABORATORIES HOLDINGS LIMITED (9)
7456224 Method for treating autism 5 2004
* 2005/0222,272 Method for treating autism 2 2004
* 2006/0002,999 Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane 16 2005
* 2006/0079,582 Memantine for the treatment of childhood behavioral disorders 0 2005
* 2006/0198,884 Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane 9 2005
* 2008/0108,643 METHOD FOR TREATING AUTISM 4 2007
* 2009/0048,348 METHOD FOR TREATING AUTISM 2 2008
* 2009/0247,644 MEMANTINE FORMULATIONS 1 2009
8834924 Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane 0 2011
 
EMORY UNIVERSITY (1)
7375136 pH-dependent NMDA receptor antagonists 2 2002
 
NEUROFIT SAS (1)
* 2006/0276,460 Use of piperazine phenothiazine derivatives in the manufacture of a medicament with neuroprotector and/or neurotrophic effects on cns and/or pns 0 2004
 
BELLUS HEALTH INC. (3)
8748656 Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid 1 2007
* 2008/0146,642 METHODS, COMPOUNDS, COMPOSITIONS AND VEHICLES FOR DELIVERING 3-AMINO-1-PROPANESULFONIC ACID 2 2007
9499480 Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid 0 2014
 
ENDO PHARMACEUTICALS INC. (2)
* 6187338 Anticonvulsant containing composition for treating neuropathic pain 63 1999
* 6406716 Anticonvulsant containing composition for treating neuropathic pain 7 2001
 
NEURONETICS, INC. (26)
7153256 Reducing discomfort caused by electrical stimulation 44 2003
* 2004/0199,041 Reducing discomfort caused by electrical stimulation 0 2003
7614996 Reducing discomfort caused by electrical stimulation 3 2003
* 2004/0199,042 Reducing discomfort caused by electrical stimulation 1 2003
7320664 Reducing discomfort caused by electrical stimulation 21 2004
* 2004/0204,625 Reducing discomfort caused by electrical stimulation 7 2004
6926660 Facilitating treatment via magnetic stimulation 35 2004
7601115 Seizure therapy method and apparatus 8 2004
* 2005/0261,542 Seizure therapy method and apparatus 66 2004
* 2006/0094,924 System and method to reduce discomfort using nerve stimulation 41 2004
7824324 Magnetic core for medical procedures 3 2005
7963903 Magnetic core for medical procedures 3 2005
* 2007/0027,353 Magnetic core for medical procedures 24 2005
8118722 Reducing discomfort caused by electrical stimulation 0 2005
* 2006/0122,454 Reducing discomfort caused by electrical stimulation 41 2005
7560058 Magnetic core for medical procedures 4 2006
* 2007/0027,354 Magnetic core for medical procedures 9 2006
8506468 Ferrofluidic cooling and acoustical noise reduction in magnetic stimulators 0 2008
* 2008/0224,808 FERROFLUIDIC COOLING AND ACOUSTICAL NOISE REDUCTION IN MAGNETIC STIMULATORS 14 2008
9308386 Magnetic core for medical procedures 0 2009
8657731 Magnetic core for medical procedures 4 2009
* 2009/0247,808 MAGNETIC CORE FOR MEDICAL PROCEDURES 0 2009
* 2009/0240,096 MAGNETIC CORE FOR MEDICAL PROCEDURES 4 2009
8246529 Magnetic core for medical procedures 2 2010
8517908 Reducing discomfort caused by electrical stimulation 1 2012
8864641 Reducing discomfort caused by electrical stimulation 0 2013
 
ALLERGAN, INC. (1)
* 2004/0254,251 Memantine oral dosage forms 12 2004
 
DEPOMED, INC. (2)
9000046 Gastric retentive dosage forms for extended release of acamprosate into the upper gastrointestinal tract 0 2011
9301934 Gastric retentive dosage forms for extended release of acamprosate into the upper gastrointestinal tract 0 2015
 
BOSTON SCIENTIFIC NEUROMODULATION CORPORATION (1)
* 2004/0225,335 Treatment of Huntington's disease by brain stimulation 39 2004
 
SYNC-THINK, INC. (2)
9265458 Application of smooth pursuit cognitive testing paradigms to clinical drug development 1 2012
9380976 Optical neuroinformatics 0 2013
 
NeurOp, Inc. (2)
8420680 NMDA receptor antagonists for neuroprotection 0 2008
9079852 NMDA receptor antagonists for neuroprotection 0 2013
* Cited By Examiner